RECRUITING

Tranexamic Acid in Nasal Mohs Reconstruction

Talk to us

Conditions

Postoperative BleedingSkin Cancer FaceTranexamic AcidMohs Reconstruction

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC.

Official Title

Subcutaneous Tranexamic Acid in Nasal Mohs Local Flap Reconstruction: Perioperative Bleeding, Edema, and Ecchymosis

Quick Facts

Study Start:2024-03-19
Study Completion:2024-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06057675

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Adults at least 18 years of age undergoing local flap reconstruction (bilobe flap, note flap dorsal nasal flap, advancement flap) of a nasal defect following Mohs micrographic surgery. Reconstructive procedures will be performed by Drs. Yang or Patel in the division of Facial Plastic Surgery in the Department of Otolaryngology, Head and Neck Surgery at Vanderbilt University Medical Center.
  2. 2. No other facial plastic procedure or sinus surgery performed simultaneously.
  3. 3. Lack of all the below exclusion criteria.
  1. 1. Known allergy to TXA
  2. 2. Intracranial bleeding
  3. 3. Known defective color vision
  4. 4. History of venous or arterial thromboembolism
  5. 5. History of coagulation disorder
  6. 6. Active thromboembolic disease
  7. 7. Severe renal impairment (diagnosis of chronic kidney disease)
  8. 8. History of acute myocardial infarction
  9. 9. History of stroke
  10. 10. History of seizure
  11. 11. History of liver failure
  12. 12. Preoperative lab results indicating thrombocytopenia (platelets \<150,000), increased bleeding risk (PT over 45, INR over 1.2).

Contacts and Locations

Study Contact

Connie Ma, MD
CONTACT
2815366877
connie.ma@vumc.org

Principal Investigator

Priyesh Patel, MD
PRINCIPAL_INVESTIGATOR
Vanderbilt University Medical Center

Study Locations (Sites)

Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States

Collaborators and Investigators

Sponsor: Vanderbilt University Medical Center

  • Priyesh Patel, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-03-19
Study Completion Date2024-12

Study Record Updates

Study Start Date2024-03-19
Study Completion Date2024-12

Terms related to this study

Keywords Provided by Researchers

  • Tranexamic Acid
  • Mohs Reconstruction

Additional Relevant MeSH Terms

  • Postoperative Bleeding
  • Skin Cancer Face